Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 June 2024 | Story Leonie Bolleurs | Photo Kaleidoscope Studios
Prof Hendrik Swart
Prof Hendrik Swart’s prolific publication record, the high impact of his work, and the outstanding quality of his scholarly contributions have placed him among the top 0,05% of all scholars worldwide.

ScholarGPS awarded Prof Hendrik Swart, Senior Professor in the Department of Physics at the University of the Free State (UFS), Highly Ranked Scholar status.

ScholarGPS celebrates Highly Ranked Scholars™ for their performance in various fields, disciplines, and specialties. Prof Swart’s prolific publication record, the high impact of his work, and the outstanding quality of his scholarly contributions have placed him among the top 0,05% of all scholars worldwide.

Prof Swart received Highly Ranked Scholar status (Lifetime) for ranking 16th in the discipline of Phosphor. Highly Ranked Scholars™ – Lifetime refers to distinguished authors, including those who are currently active, retired, or deceased. These scholars are recognised for their exceptional lifetime scholarly contributions, placing them in the top 0,05% of all scholars. Their achievements are evaluated across four categories: overall (across all fields), within their specific field of study, within their particular discipline, and across all specialties they are associated with.

Additionally, Prof Swart received Highly Ranked Scholar status (prior five years) for ranking first in Condensed Matter Physics, 42nd in Physics, 155th in Sensor, 207th in Physical Science and Mathematics, and 969th in all fields.

Scientific profile and credibility

ScholarGPS is a California-based company that applies artificial intelligence, data mining, machine learning, and other data science techniques to its massive database of more than 200 million publications and 3 billion citations to rank more than 30 million scholars and 55 000 institutions worldwide. They categorise more than 200 million scholarly publications into specific academic specialties. These specialties are further organised into 177 disciplines and 14 overarching fields. As a result of this extensive classification effort, scholars who are considered highly ranked within their respective fields can now be identified with greater precision. This identification is done not only within each academic specialty, but also across disciplines and fields, providing a comprehensive view of scholarly achievement and expertise. This system allows for the identification of top scholars within various areas of academic research in a way that was not possible before.

Prof Swart, who is an NRF B1-rated researcher, currently also holds the SARChI Research Chair: Solid-state Luminescent and Advanced Materials (2023-2027). On receiving this award from ScholarGPS, he says it is always a privilege to be recognised as one of the top scholars in your specific field, especially at this late stage of his career.

Professionally, Prof Swart says this award may boost his scientific profile and credibility in the academic community, potentially leading to more collaborations and partnerships.

In the field of condensed matter physics, the impact of his work is specifically noteworthy in the study of defects and impurities within semiconductors, along with their practical applications in optoelectronic devices. Moreover, his significant contributions extend to understanding optical and electronic properties at the nanoscale, bearing implications for the development of semiconductor technology, including light-emitting diodes (LEDs), photovoltaic cells, and quantum dots.

Primarily focused on mentorship

He believes his successes in physics and advances in understanding the universe are the result of a combination of variables, including innovative research, collaboration and networking, mentorship, effective communication, persistence, and resilience. “I am primarily focused on mentorship, which is critical to developing the next generation of physicists and creating a supportive environment for learning and discovery, as well as conducting groundbreaking research and making novel discoveries that are critical to pushing the boundaries of physics. I am always searching for opportunities to collaborate with other scholars, both inside and outside my discipline, which will result in constructive exchange of ideas, interdisciplinary discoveries, and collective problem solving.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept